Molina Healthcare stock
MOHNYSEMolina Healthcare, Inc., HealthcareISIN US60855R1005
50Score 50 out of 100, Neutral
Price and trend
77 / 100
Price history
+46% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 45).
The price is 14% below its 52-week high. Largest decline in 20 years: 71% (March 2024 to February 2026).
Chart figures for advanced users
- SMA 50$202.30
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$185.56
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)45
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$122.65
- The lowest closing price of the last twelve months.
- Resistance$242.88
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Molina Healthcare, Inc. belongs to the Medical (Healthcare Plans) industry (United States) and, with a market value of $10.92B, is number 7 of 12 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $45.43B (up 11.7% year on year) and earnings of $472M (down 60%).
- For fiscal 2026, analysts expect on average revenue of $44.72B (down 1.5%) and adjusted earnings per share of $5.26 (down 50.6%).
Show more
- MEQIRI Score 50 out of 100 (Neutral): rank 383 of 714 in Healthcare, median 53.
- Our model puts fair value at $169.69, with the price 23% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 18.5% a year since 2020, Medical (Healthcare Plans) median 11.9%.
- Share buybacksShare count down 14% since 2020.Capital allocation 50
- More cash than debtCash $8.58B, financial debt $3.95B.Stability 53
Weaknesses
- Loss-makingLoss of $48M over the last 12 months.Fundamentals 58
- Volatile share priceVolatility 50% a year over the last 12 months.Stability 53
Its standout strengths are momentum and technical analysis, while growth and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 49 to 50.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $121.21 and expensive above $282.82 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $136.89, at 7.8% it would be $219.15.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 2.1% on the twelve months before. Revenue has grown strongly since 2006, at around 18% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 9%, operating 2%, net 1%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 21 Oct 2026EPS reported $0.89 (expected $0.79)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $5.26+0.3%
- Revenue
- $44.72B+0.5%
- Earnings per share
- $9.65−0.7%
- Revenue
- $47.6B−0.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −10.9%Earnings guidance raised by $0.25 to at least $5.25 per share, driven by Medicaid and Medicare, despite the marketplace outlook being cut by $1.50.
“We have increased our full year 2026 adjusted earnings guidance by $0.25 to at least $5.25 per share. This increase to our earnings guidance reflects first half performance in Medicaid.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 23 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $114,930 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Hebert MauriceSale
14 May 2026, Chief Accounting Officer
- Shares
- 600
- Price
- $191.55
- Value
- $114,930
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Molina Healthcare
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 50
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Plans)
The next larger and next smaller companies by market value
- Elevance HealthELV $92.79B69
- CignaCI $79.43B66
- HumanaHUM $53.6B63
- CenteneCNC $34.89B54
- Oscar HealthOSCR $9.93B71
- BradsaudeSAUD3.SA $8.69B80
- ProgynyPGNY $2.69B79
- Clover Health InvestmentsCLOV $2.64B52
ETFs that hold Molina Healthcare
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.51% | 0.30% | €944.34M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.34% | 0.30% | €5.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.17% | 0.43% | €2.48B |
Show 5 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.11% | 0.35% | €8.19B |
| Invesco RAFI US Fundamental Value UCITS ETF6PSA | 0.08% | 0.39% | €1.23B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.08% | 0.35% | €434.1M |
| Invesco RAFI All-World Fundamental Value UCITS ETFPSWD | 0.04% | 0.39% | €446.84M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.03% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 12 Nov 2026, previously Weak
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.